Hikma Pharmaceuticals (HIK) Competitors

HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Which has more risk & volatility, HCM or HIK?

HUTCHMED has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Is HCM or HIK more profitable?

Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	-6.87%	-5.71%	-5.90%
Hikma Pharmaceuticals	9.45%	12.71%	9.40%

Does the media prefer HCM or HIK?

In the previous week, Hikma Pharmaceuticals had 3 more articles in the media than HUTCHMED. MarketBeat recorded 3 mentions for Hikma Pharmaceuticals and 0 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.24 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
HUTCHMED	Neutral
Hikma Pharmaceuticals	Neutral

Do analysts rate HCM or HIK?

Hikma Pharmaceuticals has a consensus target price of GBX 2,560, suggesting a potential upside of 29.69%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders hold more shares of HCM or HIK?

36.5% of HUTCHMED shares are owned by institutional investors. Comparatively, 42.1% of Hikma Pharmaceuticals shares are owned by institutional investors. 39.0% of HUTCHMED shares are owned by company insiders. Comparatively, 30.5% of Hikma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has better earnings & valuation, HCM or HIK?

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	£771.01M	3.52	-£52.98M	-£3.92	-63.81
Hikma Pharmaceuticals	£3.74B	1.46	£353.21M	£101.91	19.37

Summary

Hikma Pharmaceuticals beats HUTCHMED on 13 of the 16 factors compared between the two stocks.